Scientific Discovery by Machine Intelligence: A New Avenue for Drug Research

TL;DR

This paper introduces a novel semantic AI approach using self-organizing engines to mine biomedical texts, aiming to discover new drug biomarkers and phenotypes, potentially accelerating pharmaceutical research and reducing development costs.

Contribution

It presents a new methodology employing a self-organizing semantic engine for text mining in drug research, demonstrating initial success in identifying biomarkers for diabetes and obesity.

Findings

Successful identification of new biomarkers for diabetes and obesity

Potential to shorten drug development timelines

Impact on early detection of research dead ends

Abstract

The majority of big data is unstructured and of this majority the largest chunk is text. While data mining techniques are well developed and standardized for structured, numerical data, the realm of unstructured data is still largely unexplored. The general focus lies on information extraction, which attempts to retrieve known information from text. The Holy Grail, however is knowledge discovery, where machines are expected to unearth entirely new facts and relations that were not previously known by any human expert. Indeed, understanding the meaning of text is often considered as one of the main characteristics of human intelligence. The ultimate goal of semantic artificial intelligence is to devise software that can understand the meaning of free text, at least in the practical sense of providing new, actionable information condensed out of a body of documents. As a stepping stone on the road to this vision I will introduce a totally new approach to drug research, namely that of identifying relevant information by employing a self-organizing semantic engine to text mine large repositories of biomedical research papers, a technique pioneered by Merck with the InfoCodex software. I will describe the methodology and a first successful experiment for the discovery of new biomarkers and phenotypes for diabetes and obesity on the basis of PubMed abstracts, public clinical trials and Merck internal documents. The reported approach shows much promise and has potential to impact fundamentally pharmaceutical research as a way to shorten time-to-market of novel drugs, and for early recognition of dead ends.